Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza

This episode of Pharma Pulse discusses FDA’s growing National Priority Voucher initiative, fresh data on oral semaglutide’s cardiometabolic impact, and Mark Cuban’s latest drug addition that signals key shifts in innovation, access, and affordability across the pharmaceutical landscape.